(firstQuint)A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis.

 LCH115397 was a phase 2a, open label, multicenter study testing 125 mg (starting dose) daily oral GSK2110183 in adult and adolescent patients with Langerhans Cell Histiocytosis.

 The primary objectives of the study were efficacy (at 3 and 6 months) and safety.

 For the purpose of efficacy analysis, patients were stratified into two groups: treatment-naive (Stratum 1) and refractory or reactivation disease (Stratum 2).

 Adolescent participation was limited to patients with refractory or reactivation disease (Stratum 2).

.

 A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis@highlight

The purpose of this study was to assess safety and efficacy at months 3 and 6 in patients with Langerhans Cell Histiocytosis given daily oral doses of GSK2110183.

